E1 ReplicatedPreliminaryPEM unclearRCTPeer-reviewedMachine draft
Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome.
Natelson, B H, Cheu, J, Pareja, J et al. · Psychopharmacology · 1996 · DOI
Quick Summary
Researchers tested whether a low-dose medication called phenelzine could help ME/CFS symptoms. The study was based on the idea that ME/CFS might involve low levels of a brain chemical that normally helps the body stay energized. Patients taking the medication reported improvement in fatigue, pain, mood, and ability to function compared to those taking placebo.
Why It Matters
This study offers an evidence-based pharmacological hypothesis for ME/CFS pathophysiology—reduced sympathetic nervous system function—which could lead to targeted treatments. The rigorous blinding and control for psychiatric confounds addresses a critical historical criticism of ME/CFS research, suggesting biological rather than psychological mechanisms underlie the condition.
Observed Findings
- Patients receiving low-dose phenelzine showed significant improvement across 20 different self-report measures of CFS symptoms, illness severity, mood, and functional status compared to placebo group
- No evidence of placebo effect was detected, suggesting improvement was due to the medication rather than patients' expectations
- The three-segment treatment protocol (starting with placebo, then 15 mg every other day, then 15 mg daily) was tolerated without serious adverse events mentioned
- Patients enrolled had no clinically significant depression at baseline, demonstrating improvement occurred in non-depressed individuals
Inferred Conclusions
- Central sympathetic nervous system dysfunction may underlie ME/CFS pathophysiology, as evidenced by response to a sympathomimetic agent
- ME/CFS is not a psychosomatic illness driven by suggestion or over-suggestibility, supporting a biological disease model
- Monoamine oxidase inhibitors warrant further investigation as potential therapeutic agents in ME/CFS
Remaining Questions
- Does phenelzine demonstrate sustained efficacy and acceptable safety profiles over longer treatment periods (months to years)?
- What is the optimal dosing strategy, and does dose-response relationship exist for phenelzine in ME/CFS?
What This Study Does Not Prove
This study does not establish that phenelzine is safe or effective for widespread clinical use in ME/CFS, as it represents a single small trial from 1996 and does not provide long-term safety or efficacy data. It cannot definitively distinguish between reduced sympathetic drive and pain-related improvement as the primary mechanism. The findings do not prove ME/CFS is purely biological or rule out complex interactions between neurobiological and other factors.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
Metadata
- DOI
- 10.1007/BF02246661
- PMID
- 8740043
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →